<unk>  is indicated, in combination with chemotherapy, for the treatment of adults with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Margetuximab
Dinutuximab
Siltuximab
Isatuximab
Loncastuximab tesirine
Tucatinib
Neratinib
Fostamatinib